Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of “Buy” from Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.50.

A number of brokerages have recently weighed in on CATX. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a report on Tuesday. UBS Group upped their target price on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday. Piper Sandler initiated coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a report on Tuesday.

Key Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: UBS raised its price target for CATX to $8.00, signaling increased upside from current levels and giving investors a higher valuation reference. UBS Group Raises Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $8.00
• Positive Sentiment: B. Riley Financial analyst says CATX stock price is expected to rise, which can attract momentum buying and support higher valuations. Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Expected to Rise, B. Riley Financial Analyst Says
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on CATX, reinforcing buy-side sentiment from another boutique/specialist analyst. Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)
• Positive Sentiment: Brookline Capital Markets materially raised its FY2026 and quarter-by-quarter EPS estimates (still negative EPS, but less severe), suggesting improving expectations for the company’s financial trajectory. This reduces downside risk from prior forecasts. (Market data / analyst note)
• Positive Sentiment: BTIG initiated/maintained a Buy rating on CATX, adding further institutional buy-side support. Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Buy Rating from BTIG Research
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX, which can add short-term pressure and offset some of the positive analyst actions. Royal Bank Of Canada Has Lowered Expectations for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Perspective Therapeutics Stock Down 3.3%

NYSEAMERICAN:CATX opened at $4.45 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 5.17. The stock’s fifty day moving average is $4.37 and its two-hundred day moving average is $3.44. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. Research analysts predict that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its position in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the period. Aigen Investment Management LP acquired a new position in Perspective Therapeutics during the fourth quarter worth $28,000. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the fourth quarter worth $31,000. Engineers Gate Manager LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $35,000. Finally, AXQ Capital LP boosted its position in shares of Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.